中东和非洲体外诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按技术、产品、可用性、应用、最终用户、诊断方法和地理划分

市场快照

MIDDLE East & Africa IVD Market_1
Study Period: 2018 - 2026
Base Year: 2021
CAGR:
Market Value (2018): USD 2,286.60 million
Market Value (2024): USD 3,013.94 million

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

研究的中东和非洲体外诊断市场在 2018 年价值 22.8660 亿美元,预计到 2024 年将达到 30.1394 亿美元,在预测期间(2019-2024 年)预计复合年增长率为 4.71%。

与 IVD 行业增长相关的主要驱动因素是慢性病的高负担,特别是传染病和糖尿病以及癌症,这在很大程度上促进了 IVD 的需求和增长。公司正在与政府和非营利组织合作,以较低的成本发布自检设备。

由于慢性病的负担,中东和非洲地区受到的影响最大。造成这种负担增加的主要原因是非洲国家缺乏适当的医疗保健系统以及对新型疾病诊断技术的认识不足。南非的 HIV 感染人口数量众多,国家卫生研究所表示,在 2016-2017 年期间,该国约有 570 万人感染了 HIV。根据民间社会组织网络(2018 年)发布的报告,人们感觉到南非正在经历 NCD(非传染性疾病)的激增,例如心脏病、中风、癌症、糖尿病和慢性肺病. 由于慢性病的增加,

报告范围

体外诊断被定义为单独或组合使用的医疗设备,制造商旨在对来自人体的样本进行体外检查,单独或主要为诊断、监测或兼容性目的提供信息。

By Technique
Histochemistry
Molecular Diagnostics
Hematology
Self-blood Glucose Testing
Immunochemistry
Other Techniques
By Product
Instrument
Reagent
Other Products
By Usability
Disposable IVD Device
Reusable IVD Device
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Other Applications
By End User
Diagnostic Laboratories
Hospitals and Clinics
Other End Users
By Diagnostic Approach
Point-of-Care Diagnostics
Centralized Laboratory-based Diagnostics
Geography
GCC
South Africa
Rest of Middle East & Africa

Report scope can be customized per your requirements. Click here.

主要市场趋势

糖尿病预计将在应用领域以高复合年增长率增长

传染病、艾滋病毒/艾滋病和贫困传统上在非洲地区占主导地位,但糖尿病已成为新的优先事项。世界卫生组织(WHO)最近在非洲地区进行的调查表明,在 25 至 64 岁的成年人中,多达 15% 的人患有糖尿病。根据 IDF(国际糖尿病联盟)糖尿病地图集第 8 版,2017 年 IDF 非洲地区预计有 1550 万 20-79 岁的成年人患有糖尿病,占整个地区的 3.3%。WHO 和 IDF 估计,未来 25 年内非洲的糖尿病人口可能会翻一番。这引发了巨大的医疗保健问题,因为所有非洲国家已经在努力应对糖尿病负担。然而,世卫组织报告说,该地区的糖尿病是一种严重的、慢性的、

MIDDLE East & Africa IVD Market_2

竞争格局

中东和非洲体外诊断市场竞争激烈,由几个主要参与者组成。就市场份额而言,目前很少有主要参与者在 GCC 市场占据主导地位。市场的一些主要参与者包括雅培实验室、丹纳赫公司、Sysmex 公司、F. Hoffmann-La Roche AG 和 Becton、Dickinson 公司等。这些公司大多通过其分支机构或在国内和国际层面运营的分销商监控分销。阿拉伯联合酋长国和沙特阿拉伯主要是医疗旅游国家,因此,它们是中东和非洲地区许多公司最重要的地点。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Chronic Diseases

      2. 4.2.2 Increasing Use of Point-of-Care (PoC) Diagnostics

      3. 4.2.3 Increasing Use of Advanced Technologies

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Technique

      1. 5.1.1 Histochemistry

      2. 5.1.2 Molecular Diagnostics

      3. 5.1.3 Hematology

      4. 5.1.4 Self-blood Glucose Testing

      5. 5.1.5 Immunochemistry

      6. 5.1.6 Other Techniques

    2. 5.2 By Product

      1. 5.2.1 Instrument

      2. 5.2.2 Reagent

      3. 5.2.3 Other Products

    3. 5.3 By Usability

      1. 5.3.1 Disposable IVD Device

      2. 5.3.2 Reusable IVD Device

    4. 5.4 By Application

      1. 5.4.1 Infectious Disease

      2. 5.4.2 Diabetes

      3. 5.4.3 Cancer/Oncology

      4. 5.4.4 Cardiology

      5. 5.4.5 Autoimmune Disease

      6. 5.4.6 Other Applications

    5. 5.5 By End User

      1. 5.5.1 Diagnostic Laboratories

      2. 5.5.2 Hospitals and Clinics

      3. 5.5.3 Other End Users

    6. 5.6 By Diagnostic Approach

      1. 5.6.1 Point-of-Care Diagnostics

      2. 5.6.2 Centralized Laboratory-based Diagnostics

    7. 5.7 Geography

      1. 5.7.1 GCC

      2. 5.7.2 South Africa

      3. 5.7.3 Rest of Middle East & Africa

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Danaher Corporation

      3. 6.1.3 F. Hoffmann-La Roche AG

      4. 6.1.4 Becton, Dickinson and Company

      5. 6.1.5 BioMerieux SA

      6. 6.1.6 Siemens Healthineers

      7. 6.1.7 Thermo Fischer Scientific Inc.

      8. 6.1.8 Qiagen NV

      9. 6.1.9 Seegene Inc.

      10. 6.1.10 Sysmex Corp.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The MEA In-Vitro Diagnostics Market market is studied from 2018 - 2026.

The MEA In-Vitro Diagnostics Market is valued at 4.71% in 2018.

The MEA In-Vitro Diagnostics Market is valued at USD 2,286.60 million in 2026.

Abbott Laboratories, Danaher Corporation, Sysmex Corp., F. Hoffmann-La Roche AG, Becton, Dickinson and Company are the major companies operating in MEA In-Vitro Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!